OBJECTIVE: To determine the effect of bovine lactoferrin (bLF) on prevention of diarrhea in children. STUDY DESIGN: We conducted a community-based randomized double-blind placebo controlled trial comparing supplementation with bLF vs placebo. Previously weaned children were enrolled at 12-18 months and followed for 6 months with daily home visits for data collection and supplement administration. Anthropometric measures were done monthly. RESULTS:Five hundred fifty-five children were randomized: 277 tobLF and 278 to placebo; 65 dropped out; 147 894 doses were administered (92% compliance). Overall there were 91 446 child-days of observation and 1235 diarrhea episodes lasting 6219 days. The main pathogens isolated during diarrheal episodes were norovirus (35.0%), enteropathogenic E coli (11.4%), Campylobacter (10.6%), enteroaggregative E coli (8.4%), enterotoxigenic E coli (6.9%), and Shigella (6.6%). The diarrhea incidence was not different between groups: 5.4 vs 5.2 episodes/child/year for bLF and placebo, respectively (P = .375). However, the diarrhea longitudinal prevalence was lower in the bLF group vs placebo (6.6% vs 7.0%, P = .017), as well as the median duration of episodes (4.8 vs 5.3 days, P = .046), proportion of episodes with moderate or severe dehydration (1.0% vs 2.6%, P = .045), and liquid stools load (95.0 vs 98.6) liquid stools/child/year, P < .001). There were no adverse events related to the intervention. CONCLUSIONS: Although there was no decrease in diarrhea incidence, longitudinal prevalence and severity were decreased with LF.
RCT Entities:
OBJECTIVE: To determine the effect of bovinelactoferrin (bLF) on prevention of diarrhea in children. STUDY DESIGN: We conducted a community-based randomized double-blind placebo controlled trial comparing supplementation with bLF vs placebo. Previously weaned children were enrolled at 12-18 months and followed for 6 months with daily home visits for data collection and supplement administration. Anthropometric measures were done monthly. RESULTS: Five hundred fifty-five children were randomized: 277 to bLF and 278 to placebo; 65 dropped out; 147 894 doses were administered (92% compliance). Overall there were 91 446 child-days of observation and 1235 diarrhea episodes lasting 6219 days. The main pathogens isolated during diarrheal episodes were norovirus (35.0%), enteropathogenic E coli (11.4%), Campylobacter (10.6%), enteroaggregative E coli (8.4%), enterotoxigenic E coli (6.9%), and Shigella (6.6%). The diarrhea incidence was not different between groups: 5.4 vs 5.2 episodes/child/year for bLF and placebo, respectively (P = .375). However, the diarrhea longitudinal prevalence was lower in the bLF group vs placebo (6.6% vs 7.0%, P = .017), as well as the median duration of episodes (4.8 vs 5.3 days, P = .046), proportion of episodes with moderate or severe dehydration (1.0% vs 2.6%, P = .045), and liquid stools load (95.0 vs 98.6) liquid stools/child/year, P < .001). There were no adverse events related to the intervention. CONCLUSIONS: Although there was no decrease in diarrhea incidence, longitudinal prevalence and severity were decreased with LF.
Authors: Robert E Black; Simon Cousens; Hope L Johnson; Joy E Lawn; Igor Rudan; Diego G Bassani; Prabhat Jha; Harry Campbell; Christa Fischer Walker; Richard Cibulskis; Thomas Eisele; Li Liu; Colin Mathers Journal: Lancet Date: 2010-05-11 Impact factor: 79.321
Authors: Theresa J Ochoa; Lucie Ecker; Francesca Barletta; Mónica L Mispireta; Ana I Gil; Carmen Contreras; Margarita Molina; Isabel Amemiya; Hector Verastegui; Eric R Hall; Thomas G Cleary; Claudio F Lanata Journal: Clin Infect Dis Date: 2009-12-01 Impact factor: 9.079
Authors: Anicia M Medina; Fulton P Rivera; Maria J Pons; Maribel Riveros; Cláudia Gomes; María Bernal; Rina Meza; Ryan C Maves; Luis Huicho; Elsa Chea-Woo; Claudio F Lanata; Ana I Gil; Theresa J Ochoa; Joaquim Ruiz Journal: Trans R Soc Trop Med Hyg Date: 2015-08 Impact factor: 2.184
Authors: Angela Lluque; Susan Mosquito; Cláudia Gomes; Maribel Riveros; David Durand; Drake H Tilley; María Bernal; Ana Prada; Theresa J Ochoa; Joaquim Ruiz Journal: Int J Med Microbiol Date: 2015-05-04 Impact factor: 3.473
Authors: Millie R Chang; Grace Velapatiño; Miguel Campos; Elsa Chea-Woo; Nelly Baiocchi; Thomas G Cleary; Theresa J Ochoa Journal: Am J Trop Med Hyg Date: 2015-03-16 Impact factor: 2.345
Authors: Erik H Mercado; Cristian Piscoche; Carmen Contreras; David Durand; Maribel Riveros; Joaquim Ruiz; Theresa J Ochoa Journal: Int J Med Microbiol Date: 2016-05-10 Impact factor: 3.473
Authors: Mara Zambruni; Giannina Luna; Maria Silva; Daniel G Bausch; Fulton P Rivera; Grace Velapatino; Miguel Campos; Elsa Chea-Woo; Nelly Baiocchi; Thomas G Cleary; Theresa J Ochoa Journal: J Pediatric Infect Dis Soc Date: 2015-02-04 Impact factor: 3.164